Gregg C. Fonarow works in Heart Failure / Cardiomyopathy affiliated with University of California, Los Angeles.
Gregg C. Fonarow, MD, is the Eliot Corday Professor of Cardiovascular Medicine and Science at the David Geffen School of Medicine at UCLA. He serves as Director of the Ahmanson-UCLA Cardiomyopathy Center and Co-Director of the UCLA Preventative Cardiology Program. He served as Interim Chief of the UCLA Division of Cardiology from 2020 to 2024.
3,014 pubs · 190,731 cites · h-index 193
MD
David Geffen School of Medicine at UCLA
1987
Eliot Corday Professor of Cardiovascular Medicine and Science; Director, Ahmanson-UCLA Cardiomyopathy Center; Co-Director, UCLA Preventative Cardiology Program
David Geffen School of Medicine at UCLA · 2003 - Present
Interim Chief, Division of Cardiology
UCLA Division of Cardiology · 2020 - 2024
Clinical Co-Chief, Cardiology
UCLA Division of Cardiology · 2013 - Present
American Journal of Cardiovascular DrugsJaiswal et al.meta-analysis
Colchicine prophylaxis reduces postoperative atrial fibrillation after cardiac surgery; confirms prior RCT findings and supports guideline consideration.
JACCLam et al.cohort
In hospitalized older patients with HFpEF, a discharge heart rate <70 beats/min is independently associated with a lower risk of long-term all-cause mortality, though it does not significantly reduce hospital readmissions.
CirculationJacobs et al.Guideline
Circulation Population Health and OutcomesGirard et al.cross-sectional
KCCQ domains may support integrated assessment without age/sex adjustment in HFrEF; extends interrelationship mapping but leaves open longitudinal validation.
JAMA Network OpenRoyan et al.Cohort Study
Importance Clinical data comparing time to presentation and stroke quality metrics for intracerebral hemorrhage (ICH) and acute ischemic stroke ( AIS ) are limited. Understanding these differences is essential to provide timely care to all stroke subtypes. Objective To compare prehospital and emergency department (ED) process quality metrics between patients with ICH and AIS. Design, Setting, and Participants Cohort study included patients with AIS and ICH admitted to Get With The Guidelines (GWTG)–Stroke participating hospitals from January 1, 2015, to June 30, 2024, who arrived by emergency medical services (EMS). Data were analyzed from 195 hospitals across the US. Main Outcomes and Measures Prehospital-based and ED-based process metrics (eg, EMS prenotification, door to ED physician assessment time, door to initial brain imaging order) were assessed. Logistic and linear regression models were sequentially adjusted for patient demographics, medical history and presenting factors, and hospital characteristics. Temporal trends of prehospital care metrics were examined. Results A total of 195 659 patients (median [IQR] age, 74.0 [63.0-83.0] years; 97 978 [50.1%] female; 31 464 with ICH and 164 195 with AIS) from 195 hospitals were included. The median (IQR) National Institutes of Health Stroke Scale (NIHSS) score was 14 (6-23) for ICH vs 6 (2-13) for AIS (absolute standardized difference, 0.694). ICH (vs AIS) was associated with higher odds of door-to-ED physician assessment of 10 or fewer minutes after adjusting for patient demographics (adjusted odds ratio [aOR], 1.08; 95% CI, 1.02-1.14). This association reversed after adding adjustment for medical history and presenting factors (including NIHSS) and hospital characteristics (aOR, 0.94; 95% CI, 0.89-0.99). This pattern was observed for door to initial brain imaging order of 20 or fewer minutes (demographic-adjusted: aOR, 1.09; 95% CI, 1.02-1.16; fully adjusted with medical history and hospital characteristics: aOR, 0.91; 95% CI, 0.85-0.97). Median last known well to arrival time increased by 32.5% for AIS (151 to 200 minutes; P < .001) and 34.3% for ICH (108 to 145 minutes; P < .001), while rates of EMS prenotification largely remained stable for both ICH and AIS. Conclusions and Relevance In this cohort study of patients with acute stroke, patients with ICH arrived at the ED faster but were less likely to achieve care targets. In the context of emerging hyperacute ICH therapies and bundled care models, addressing these differences is essential to optimizing acute stroke outcomes.
The American Journal of MedicineNations et al.cohort
The Cardiovascular Health Study tracked 2,758 older adults living in the community by their baseline pulmonary artery acceleration time on echo, an estimate of lung artery pressure. Over a median 13.4 years, 85.5% of those with a time under 100 ms died, versus 75.2% above 130 ms. The catch: this link was no longer significant after full adjustment for underlying heart disease and systemic biomarkers. The echo measure reflects broader heart and overall health rather than lung disease alone.
Heart Failure / Cardiomyopathy · University of California, Los Angeles
The number of contraindications here are relatively few. Hemodynamic intolerance is almost nonexistent in those patients with the EFs of 40 and above.
JAMA CardiologyGreene et al.
Heart Failure / Cardiomyopathy · University of Copenhagen
Across a broad range of ages, these therapies, when implemented in combination, may meaningfully improve life expectancy and help patients remain out of the hospital.
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)Vaduganathan et al.
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)Arundel et al.cohort
Target-dose ACE inhibitor initiation was associated with lower mortality in hospitalized HFrEF; leaves open whether randomized trials should confirm this before practice change.
European Journal of Heart FailureAhmed et al.Original Research
Journal of Cardiac FailureVarshney et al.cohort
Intensive diuretic strategies in acute heart failure lead to better in-hospital decongestion but do not directly translate to lower 90-day readmission or death in real-world practice, although successful weight loss itself is associated with modestly improved outcomes.
European Journal of Heart FailureLu et al.cohort
Target-dose ACE inhibitors were associated with lower kidney failure risk but no mortality benefit in HFpEF; leaves open optimal dosing pending randomized trials.
General Cardiology · American College of Cardiology
The data to date still do not indicate that PCI, really under any circumstance outside of acute coronary syndromes, prolongs life, and therefore I think [it's important to emphasize] a more conservative approach…. What's happening in practice got a bit ahead of the evidence.
CirculationFihn et al.
JACCSteimle et al.cohort
A significant minority of patients with recent onset dilated cardiomyopathy referred for heart transplantation experience marked spontaneous improvement in LV function, which can be predicted by shorter symptom duration, lower filling pressures, and higher serum sodium levels, potentially avoiding unnecessary transplantation.
Mechanical Circulatory Support Devices · Kaiser Permanente San Francisco Medical Center
These findings refine the ability to apply CPX results when making clinical decisions, and tailor interpretations of the results to a particular patient. One of the most important findings from this study is the sex-related differences. Exercise capacity appears to be a particularly important predictor in women. Peak VO2 is a strong predictor as well; however, the cutpoint used to identify women at increased risk of mortality appears to be much lower than current values.
Journal of the American College of CardiologyKeteyian et al.
Clinical and Applied Thrombosis/HemostasisSarwar et al.meta-analysis
Supports OAC monotherapy to reduce bleeding; reinforces evidence favoring de-escalation over dual antithrombotic therapy.
Journal of Cardiac FailureFonarow et al.Original Research
Low sMRA initiation rates in new HF signal persistent implementation gaps; leaves open whether targeted CKM interventions can safely improve uptake.
The American Journal of MedicineSheriff et al.cohort
Supports pathophysiological basis for SBP-mortality paradox in HFrEF; leaves open whether BP targets warrant adjustment in this population.
Clinical CardiologyKhan et al.cohort
May support RSV vaccination in older HF adults; hypothesis-generating and requires RCTs before changing practice.
Heart Failure / Cardiomyopathy · University Hospitals of Cleveland
A sobering finding is that despite the availability of highly effect medical therapy, it is underutilized. Only about 18% of patients with HFrEF are on all four pillars of guideline-directed medical therapy. Fewer than 1% reach target doses. Full implementation could save roughly 95,000 lives a year in North America. So the gap is not mainly a gap in knowledge or in drugs. It is a gap in implementation, access and care delivery.
Journal of Cardiac FailureGorodeski et al.
